IUPHAR Review - Novel therapeutic targets for schizophrenia treatment: a translational perspective DOI Creative Commons
Veronica Begni,

Alessia Marchesin,

Marco Andrea Riva

et al.

Pharmacological Research, Journal Year: 2025, Volume and Issue: unknown, P. 107690 - 107690

Published: March 1, 2025

Schizophrenia is a severe and debilitating psychiatric disorder that profoundly impacts cognitive, emotional, social functioning. Despite its devastating personal societal toll, current treatments often provide only partial relief, underscoring the urgent need for innovative therapeutic strategies. This review explores emerging approaches target complex neurobiological underpinnings of schizophrenia, moving beyond traditional dopamine-centric models. Among these, some novel drugs still employ multimodal mechanisms, simultaneously targeting dopaminergic serotonergic systems to enhance efficacy tolerability. Given well-documented excitatory/inhibitory imbalance in significant efforts have been directed toward addressing NMDA receptor hypofunctionality. However, strategies this pathway yet demonstrate consistent clinical efficacy. In contrast, therapies cholinergic system shown greater promise. For instance, xanomeline-trospium combination, which modulates muscarinic receptors, has recently gained approval, other molecules with similar mechanisms are currently under development. Beyond these approaches, being explored pathways, including neuroplasticity, neuroinflammation, mitochondrial dysfunction. These designed as part combinatorial strategy available antipsychotic drugs. progress, challenges remain translating experimental discoveries into effective applications. Future research should prioritize biomarker-driven precision medicine optimize individualized treatment outcomes. By integrating targets, schizophrenia may evolve more comprehensive personalized approach, disorder's full spectrum symptoms improving patient quality life.

Language: Английский

Role of Glial Cells and Receptors in Schizophrenia Pathogenesis DOI
Yousef Tizabi, Marta C. Antonelli,

Daniela Tizabi

et al.

Neurochemical Research, Journal Year: 2025, Volume and Issue: 50(2)

Published: Jan. 27, 2025

Language: Английский

Citations

0
Progress in the study of oxidative stress damage in patients with schizophrenia: challenges and opportunities DOI Creative Commons

K Zhang,

Lijing Zou, Yi Cai

et al.

Frontiers in Psychiatry, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 21, 2025

Schizophrenia is a serious psychiatric disorder of multifactorial triggers, with lifetime prevalence about 1% in all countries the world, slightly higher males than females, and peak incidence between ages 15-35 years old, poor prognosis for most patients, which imposes heavy burden on society family. Early intervention important regression patients. More more studies have found that imbalance oxidation antioxidant, persistent damage to brain by oxidative stress play an role occurrence development schizophrenia. Antioxidants, as additive therapy, improving symptoms well preventing relapse patients This paper intends address pathogenesis injury schizophrenia, significance treatment

Language: Английский

Citations

0
Understanding Stigma in Mental Illness: A Novel Literature-Based Model of Development DOI Creative Commons
Jorge Magalhães Rodrigues, Ana Rita Cruz, Cristina Queirós

et al.

Psychiatry International, Journal Year: 2025, Volume and Issue: 6(1), P. 21 - 21

Published: Feb. 22, 2025

The concept of stigma has evolved, initially denoting a mark shame and now encompassing broader range negative societal perceptions. Cognitive-social models describe as containing stereotypes, discrimination, prejudice, with each dimension significantly impacting individuals’ health, social interactions, willingness to seek help. This study the objective exploring main theories about propose novel model that integrates these dimensions, illustrating their interactions cumulative impact on individuals families. aims for comprehensive understanding development in mental illness provides valuable insights developing targeted anti-stigma interventions, ultimately improving lives

Language: Английский

Citations

0
IUPHAR Review - Novel therapeutic targets for schizophrenia treatment: a translational perspective DOI Creative Commons
Veronica Begni,

Alessia Marchesin,

Marco Andrea Riva

et al.

Pharmacological Research, Journal Year: 2025, Volume and Issue: unknown, P. 107690 - 107690

Published: March 1, 2025

Schizophrenia is a severe and debilitating psychiatric disorder that profoundly impacts cognitive, emotional, social functioning. Despite its devastating personal societal toll, current treatments often provide only partial relief, underscoring the urgent need for innovative therapeutic strategies. This review explores emerging approaches target complex neurobiological underpinnings of schizophrenia, moving beyond traditional dopamine-centric models. Among these, some novel drugs still employ multimodal mechanisms, simultaneously targeting dopaminergic serotonergic systems to enhance efficacy tolerability. Given well-documented excitatory/inhibitory imbalance in significant efforts have been directed toward addressing NMDA receptor hypofunctionality. However, strategies this pathway yet demonstrate consistent clinical efficacy. In contrast, therapies cholinergic system shown greater promise. For instance, xanomeline-trospium combination, which modulates muscarinic receptors, has recently gained approval, other molecules with similar mechanisms are currently under development. Beyond these approaches, being explored pathways, including neuroplasticity, neuroinflammation, mitochondrial dysfunction. These designed as part combinatorial strategy available antipsychotic drugs. progress, challenges remain translating experimental discoveries into effective applications. Future research should prioritize biomarker-driven precision medicine optimize individualized treatment outcomes. By integrating targets, schizophrenia may evolve more comprehensive personalized approach, disorder's full spectrum symptoms improving patient quality life.

Language: Английский

Citations

0